Because CCA is an accurate and useful measure of ALT activity in vitro [16], we determined if a blood-based CCA could be an accurate test for ALT+ cancer on serum specimens from 35 high-risk neuroblastoma patients whose ALT status had been determined by CCA (with PCR detection) performed on matching tumor specimens [22]. This evidence concerns the gene GPT and cancer.